Corcept Therapeutics filings document the regulatory record of a commercial-stage pharmaceutical company focused on cortisol modulation. Recent Form 8-K reports cover operating results, Regulation FD corporate updates, FDA approval of Lifyorli, clinical-trial disclosures for relacorilant programs, patent-dispute developments involving Korlym and material distribution arrangements for Korlym and authorized generic mifepristone.
The company’s proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. Its SEC record also identifies CORT common stock listed on Nasdaq and provides formal disclosures on governance, capital structure, business risks, product regulation, intellectual property and commercialization matters.
Robb Gary Charles reported acquisition or exercise transactions in this Form 4 filing.
Corcept Therapeutics granted Chief Business Officer Gary Charles Robb stock options covering 140,000 shares on February 27, 2026. These options vest in equal monthly installments over four years starting on February 27, 2026, subject to his continued service through each vesting date.
Corcept Therapeutics reported that Chief Development Officer William Guyer received a grant of stock options to acquire 140,000 shares of the company’s stock. The options were awarded at an exercise price of $0.00 per share, reflecting a compensatory award rather than an open-market purchase.
The options begin vesting on February 27, 2026 and will vest in equal monthly installments over a four-year period, contingent on Guyer’s continued service through each vesting date. Following this award, he holds stock options covering 140,000 shares directly.
Corcept Therapeutics director James N. Wilson reported several equity moves involving stock options and trust-related holdings. He exercised stock options for 100,000 shares of common stock at an exercise price of $3.88 per share through a derivative conversion.
Of the resulting shares, 10,636 shares of common stock were disposed of to cover the exercise price or tax liability at a price of $36.48 per share in a tax-withholding transaction. He then made a bona fide gift of 89,364 shares of common stock, transferring them without consideration to the James N. Wilson and Pamela D. Wilson Trust.
The filing shows 1,134,532 shares of common stock held indirectly by the James N. Wilson and Pamela D. Wilson Trust, 901,067 shares held indirectly by James and Pamela Wilson Family Partners, and 200,000 shares each held indirectly by the James N. Wilson 2025 Grantor Retained Annuity Trust and the Pamela D. Wilson 2025 Grantor Retained Annuity Trust. Wilson has voting power over the trust and partnership shares pursuant to voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest.
Corcept Therapeutics is a commercial-stage biopharma focused on diseases driven by the stress hormone cortisol, including hypercortisolism, several solid tumors, liver disease and ALS. It already markets Korlym and an authorized generic in the United States for Cushing’s syndrome–related hypercortisolism.
The company’s lead selective cortisol modulator, relacorilant, received an FDA Complete Response Letter for hypercortisolism despite positive GRACE and GRADIENT data, and Corcept is working with the agency on a new approval path. Relacorilant plus nab-paclitaxel showed meaningful progression-free and overall survival benefits in platinum‑resistant ovarian cancer, supporting U.S. and EU marketing applications with a PDUFA date of July 11, 2026. Corcept is also advancing selective modulators miricorilant for MASH, dazucorilant for ALS (with Fast Track and orphan status, and a planned Phase 3 in 2026), and nenocorilant in combination with immunotherapy, funded by increasing R&D spending across a broad pipeline.
Corcept Therapeutics reported solid 2025 growth while earnings declined as it increased spending on development and commercialization. Revenue rose to $761.4 million from $675.0 million, and fourth-quarter revenue grew to $202.1 million from $181.9 million.
Full-year net income fell to $99.7 million from $141.2 million as selling, general and administrative expenses climbed to $448.7 million. The company ended 2025 with $532.4 million in cash and investments and spent $245.9 million on share repurchases and equity-related payments. It issued 2026 revenue guidance of $900–$1,000 million and highlighted an extensive pipeline, including NDAs for relacorilant in Cushing’s syndrome and platinum-resistant ovarian cancer, Phase 2b MASH data expected by the end of 2026, and plans for a Phase 3 ALS trial of dazucorilant.
Corcept Therapeutics reported that the United States Court of Appeals for the Federal Circuit has found that Teva Pharmaceuticals’ marketing of a generic version of Korlym® does not infringe two Corcept patents covering methods of safely co‑administering Korlym with CYP3A4‑inhibiting drugs commonly used by patients with Cushing’s syndrome.
The decision affirms a prior December 2023 verdict from the Federal District Court for the District of New Jersey. Corcept’s CEO said the company is disappointed with the ruling and plans to vigorously defend its intellectual property, including evaluating options to seek further judicial review of the decision.
Corcept Therapeutics officer Sean Maduck, President of Corcept Endocrinology, reported several indirect ownership changes in Corcept common stock dated January 8, 2026. Entities associated with him made bona fide gifts of 20,570 and 34,000 shares held indirectly through the Sean and Molly Maduck Living Trust and a related trust, each at a stated price of $0.00 per share. Corresponding entries show 20,570 shares held by MMM 2025, LLC and 34,000 shares held by the SNM 2026 Grantor Retained Annuity Trust, both entities associated with Maduck. He also reports 8,179 shares held directly, which include unvested restricted stock awards scheduled to vest one year after their respective grant dates if service conditions are met, plus additional indirect holdings through another grantor retained annuity trust and Duckhill Capital, LLC.
Corcept Therapeutics Incorporated received an updated ownership report from investment manager Renaissance Technologies LLC and its parent, Renaissance Technologies Holdings Corporation. As of December 31, 2025, they report beneficial ownership of 5,758,528 shares of Corcept common stock, representing 5.47% of the outstanding class.
Renaissance reports sole power to vote and dispose of all these shares, with no shared voting or dispositive power. The filing notes that certain funds managed by Renaissance Technologies LLC have the right to receive dividends and sale proceeds, and states the position is held in the ordinary course of business, not to change or influence control of Corcept.
Corcept Therapeutics Chief Scientific Officer Hazel Hunt reported an option exercise and related share withholding. On February 9, 2026, Hunt exercised stock options for 150,000 shares of common stock at an exercise price of $3.88 per share, converting a stock option that was fully exercisable and scheduled to expire on February 26, 2026.
To cover the option exercise price and associated tax withholding in a net (cashless) transaction, 77,968 common shares were withheld at a price of $41.31 per share. After these transactions, Hunt directly held 255,437 shares of Corcept Therapeutics common stock.
Corcept Therapeutics Chief Development Officer William Guyer reported an option exercise and share sale. On February 3, 2026, he exercised a stock option for 20,000 shares of common stock at $21.65 per share and then sold 20,000 shares at a weighted average price of $40.8667 under a prearranged Rule 10b5-1 trading plan adopted on November 27, 2024. After these transactions, he directly held 1,235 shares of common stock and 230,000 stock options that are fully exercisable.